Side effects have largely resolved or become manageable
We are seeing a surge in patents for combination therapiesspecifically GLP-1s paired with myostatin or ActRII pathway modulators designed to protect muscle while deepening fat reduction
People are doing it rarely
Back Pi-Sunyer, X, Astrup A, Fukuoka, K, et al (2 July 2015) 'Obesity and prediabetes NN8022-1839 study group
Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following: Persistent or severe vomiting that prevents adequate fluid or food intake Signs of dehydration , including dizziness, reduced urination, or extreme thirst Severe or persistent abdominal pain , which may rarely indicate pancreatitis or a gallbladder problem Right upper quadrant pain, fever, or jaundice , which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) a recognised risk with GLP-1-based therapies and with rapid weight loss [11] [12] Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion Injection site reactions that are worsening, infected, or not resolving Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available
